National Research Center for Hematology, Russia

• Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  Phase 3, Active, not recruiting, 60 people, Jan 3, 2024

• NCT05425654

  Phase 2, Status unknown, 30 people, Jun 21, 2022

• NCT05158608

  Phase 3, Status unknown, 100 people, Dec 15, 2021

• NCT04578847

  Phase 2, Status unknown, 100 people, Oct 8, 2020

• NCT02270307

  Phase 2/3, Status unknown, 40 people, Oct 21, 2014

• NCT01941394

  Phase 2, Status unknown, 70 people, Sep 13, 2013

Sources: clinicaltrials.gov